Judith M. Matthews - 31 Jul 2026 Form 4 Insider Report for Eton Pharmaceuticals, Inc. (ETON)

Reporting relationship: Chief Financial Officer
Issuer ticker: ETON
Reported as of: 31 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Aug 2026, 17:04:31 UTC
Prior SEC filing: 01 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Judith Matthews

Key filing fact

Judith M. Matthews filed Form 4 for Eton Pharmaceuticals, Inc. (ETON) on 04 Aug 2026.

Key facts

This page summarizes Judith M. Matthews's Form 4 filing for Eton Pharmaceuticals, Inc. (ETON).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Aug 2026, 17:04.

Change

Previous filing in this sequence was filed on 01 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001734033 Primary reporting owner

Matthews Judith M.

Relationship: Chief Financial Officer
Address: C/O ETON PHARMACEUTICALS, INC., 21925 W. FIELD PARKWAY, SUITE 235, DEERPARK
Signature: /s/ Judith Matthews
Signature date: 04 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ETON transaction Derivative

Common Stock

Award

Transaction value
Shares: +32,246
Change %
Price: $0.000000^*
Shares after: 32,246
Date: 31 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,246
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On July 31, 2026, the reporting person was granted 32,246 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.

SEC remarks

The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.